1. Introduction {#sec1-medicines-06-00088}
===============

Prurigo nodularis (PN) is a chronic pruritic condition that is characterized by repeated scratching behavior and the presence of multiple, intensely itchy nodules \[[@B1-medicines-06-00088]\]. These lesions often are excoriated to the point of ulceration and are symmetrically distributed on the extensor surfaces of the limbs and trunk \[[@B2-medicines-06-00088]\]. PN has a significant impact on the quality of life and is linked with numerous systemic and psychological comorbidities, such as anxiety, depression, and sleep disturbance, as has been found with other pruritic conditions, like atopic dermatitis \[[@B3-medicines-06-00088],[@B4-medicines-06-00088],[@B5-medicines-06-00088],[@B6-medicines-06-00088],[@B7-medicines-06-00088]\]. Recent studies on the pathogenetic mechanisms of PN has revealed the importance of pro-inflammatory cytokines, such as IL-31, and neuropeptides in lesional skin that may contribute to altered nerve density and increased inflammation in PN \[[@B8-medicines-06-00088],[@B9-medicines-06-00088],[@B10-medicines-06-00088]\]. Despite the tremendous burden of disease of PN, there is very little known about the etiology and epidemiology of PN. A German study examined 108 PN patients in a predominantly Caucasian population and observed a female predominance (64%) with a median age of 61.5 years and found that more than half of PN cases had an atopic predisposition or concomitant atopic dermatitis \[[@B2-medicines-06-00088]\]. In fact, Tanaka et al describe two distinct forms of PN: An early-onset atopic form and a late-onset non-atopic form \[[@B11-medicines-06-00088]\]. Our group also recently described a cohort of PN patients seen in the Johns Hopkins Health System, though epidemiologic conclusions are difficult to draw based on a single health system experience \[[@B5-medicines-06-00088],[@B12-medicines-06-00088]\].

One potential reason for the limited amount of epidemiologic data available is that PN is fairly uncommon, and in the past was grouped together with other chronic pruritic conditions in previous disease classification systems \[[@B1-medicines-06-00088]\]. However, in 2015, the United States transitioned to the new disease classification system, International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), from the previously used ICD-9-CM, allowing for increased specificity in disease coding. For the first time, PN received a dedicated diagnosis code, enabling new avenues for epidemiologic research on PN to be explored.

Previous studies have demonstrated an association between PN and several comorbidities, such as HIV infection, hepatitis, congestive heart failure, chronic kidney disease, Type 2 diabetes mellitus, and several psychiatric conditions \[[@B5-medicines-06-00088]\]. These conditions contribute to PN's burden of disease and may affect hospitalization and cost of care. Due to the limited research on PN as a disease entity, little is known on the inpatient burden of PN in the United States. In the current study, we analyze the epidemiology and inpatient burden of PN in the United States, as well as factors associated with hospitalization for PN in a nationally representative database of hospitalizations in 2016.

2. Materials and Methods {#sec2-medicines-06-00088}
========================

2.1. Data Source {#sec2dot1-medicines-06-00088}
----------------

We analyzed data from the National Inpatient Sample (NIS) from 2016. The NIS is administered by the Healthcare Cost and Utilization Project (HCUP) of the Agency for Healthcare Research and Quality. Each year of data represented a stratified sample of approximately 20% of all inpatient hospitalizations within the United States. Of note, 2016 was the first complete year that prurigo nodularis received an independent diagnostic code as detailed below. Sample weights provided by NIS were used to account for sampling design of hospitals to determine nationally representative estimates. The study was exempt from the institutional review board because the database was deidentified before use.

2.2. Selection of Prurigo Nodularis Cohort {#sec2dot2-medicines-06-00088}
------------------------------------------

Patients with a diagnosis of prurigo nodularis were selected using ICD-10-CM codes. An ICD-10-CM code of L28.1 corresponded to a diagnosis of prurigo nodularis.

2.3. Statistical Analysis {#sec2dot3-medicines-06-00088}
-------------------------

Data analysis was performed using survey models that accounted for NIS-provided survey weights, sampling clusters, and strata using Stata version 15 (StataCorp, College Station, TX, USA). We determined the estimated prevalence of hospitalization for PN. Cost of inpatient care was determined based on the total reported charge of hospitalization and the all-payer inpatient cost-to-charge ratio estimates for hospitals provided by HCUP.

The control group included all discharges with no diagnosis of PN, representing the population of hospitalized patients in the United States. In order to determine risk factors for hospitalization of patients diagnosed with PN, binary logistic models were constructed using hospitalization with PN as the dependent variable. Independent variables included age, gender, race/ethnicity, the median annual income of the hospital ZIP code, health insurance type, season of admission, hospital location, teaching status, and hospital bed capacity. A *p*-value of \<0.05 was considered significant with Bonferroni correction.

3. Results {#sec3-medicines-06-00088}
==========

There was a total of 7,135,090 discharges reported in the NIS dataset during 2016. There were 265 hospitalized patients with a diagnosis of PN (weighted 1325, 95% confidence interval (CI) (1120--1530)) or 3.7 inpatient visits per 100,000 discharges in 2016.

3.1. Factors Associated with Hospitalization for Prurigo Nodularis {#sec3dot1-medicines-06-00088}
------------------------------------------------------------------

Patients admitted as inpatients to hospitals with a diagnosis of PN were on average older than patients without a diagnosis of PN (mean ± SD 55.2 ± 0.9 years vs. 49.0 ± 0.2 years, respectively). Patients with PN were more likely to be black (survey-weighted logistic regression; odds ratio (OR) 4.43, 95% CI (3.33--6.08), *p* \< 0.001), Hispanic (OR 1.77, 95% CI (1.09--2.88), *p* = 0.02), or Asian (OR 3.44, 95% CI (1.39--5.08), *p* = 0.003) compared with white patients ([Figure 1](#medicines-06-00088-f001){ref-type="fig"}). Black PN patients were more likely to be male than black patients of the general patient population (59.1% vs. 41.1%; OR 1.97, 95% CI (1.36--2.85), *p* = 0.0003). PN patients were also more likely to have Medicare (OR 2.81, 95% CI (1.80--4.39), *p* \< 0.001) or Medicaid (OR 2.24, 95% CI (1.44--3.47), *p* \< 0.001), as compared to patients with private insurance. In the US, Medicare and Medicaid are government-run programs that provide health insurance to the elderly and low-income. Hospitalized patients with PN were more likely to be seen in teaching hospitals (OR 2.60, 95% CI (1.76--3.84), *p* \< 0.001) compared to non-teaching and hospitals with a large bed capacity (OR 2.15, 95% CI (1.41--3.27), *p* \< 0.001).

In multivariate logistic regression models with stepwise elimination, age, race/ethnicity, insurance status, teaching status, and hospital bed size were found to have a statistically significant contribution to hospitalization for PN ([Table 1](#medicines-06-00088-t001){ref-type="table"}). The factors of sex, income quartile, season, and hospital region were found to have no statistically significant contribution to hospitalization for PN.

3.2. Length of Stay and Cost of Care {#sec3dot2-medicines-06-00088}
------------------------------------

The length of stay (LOS) in the hospital was longer in duration for patients with a diagnosis of PN compared with patients without PN (mean ± SD, 6.51 ± 0.37 days vs. 4.62 ± 0.02 days, *p* \< 0.001). In multivariate linear regression for LOS in patients diagnosed with PN, older age (≥18 years) was associated with a longer duration of hospital stay (beta coefficient = 3.46, 95% CI \[0.93--5.99\], *p* = 0.007) ([Table 2](#medicines-06-00088-t002){ref-type="table"}).

The total cost of care for hospitalized patients diagnosed with PN was \$18,686,522 in 2016; however, the actual total cost was higher because 12 patients had missing values for cost. The average cost of care was higher in patients diagnosed with PN compared with patients without PN (\$14,772 ± \$964 vs. \$11,728 ± \$106, *p* \< 0.001). In multivariate linear regression for cost of care in patients diagnosed with PN, older age (≥18 years) was associated with increased cost (age under 18 years: Beta coefficient = \$8,980, 95% CI (2,271.54--15,688.7), *p* = 0.009) ([Table 2](#medicines-06-00088-t002){ref-type="table"}).

3.3. Primary Reason for Admission of Prurigo Nodularis Patients {#sec3dot3-medicines-06-00088}
---------------------------------------------------------------

The most common reasons for admission to the hospital for patients diagnosed with PN were sepsis (11.7%), cellulitis (7.9%), acute exacerbation of congestive heart failure (7.5%), HIV (5.7%), pneumonia (3.4%), and end stage renal disease (3.0%) ([Figure 2](#medicines-06-00088-f002){ref-type="fig"}). Patients with PN were significantly more likely to be admitted due to HIV complications compared to the general inpatient population (OR 78.2, 95% CI (46.4--131.8), *p* \< 0.001). Furthermore, PN patients with concomitant HIV were significantly more likely to be black than white (OR 8.2, 95% CI (1.02--66.0), *p* = 0.048).

4. Discussion {#sec4-medicines-06-00088}
=============

This study represents the first epidemiological investigation of PN employing a national dataset in the United States to be reported in the literature. We estimate that approximately 1325 patients diagnosed with PN were hospitalized in the United States in 2016 or 3.7 inpatients per 100,000 discharges. These PN patients had both longer hospital stays and increased costs of care as compared to the general inpatient population. This is likely to be an underestimation of the overall PN inpatient burden as there is a lack of disease awareness among most physicians, and many patients do not receive inpatient dermatology consultations. We demonstrate that PN patients are more likely than the general population to be older in age, particularly in the 40 to 59 years age range and that increased age was associated with longer hospital stay and increased the cost of care. We attribute these age-related differences to the increased concomitant systemic comorbidities with age, such as diabetes mellitus and chronic kidney disease, which are systemic causes themselves of chronic pruritus and have been found to be associated with PN \[[@B5-medicines-06-00088]\].

Our study also demonstrates increased rates of hospitalization in PN patients who were non-white, demonstrating racial disparities in the presentation of PN. In particular, these results confirmed recent findings indicating that PN disproportionately affected blacks \[[@B5-medicines-06-00088]\]. Indeed, among the different races studied, blacks had the greatest likelihood of having PN. As previously described, black PN patients were also more likely than whites, Asians, or Hispanics to have concomitant HIV infection \[[@B5-medicines-06-00088]\]. We found that black patients with a PN diagnosis were significantly more likely to be male compared to the general population of black patients. Recent findings have demonstrated that out of all new HIV diagnoses to black individuals in 2017, 76% were male, which may explain the increased likelihood of black males with PN \[[@B13-medicines-06-00088]\].

Interestingly, infections including cellulitis and sepsis were frequent reasons for admission among patients with PN. Excoriation of skin nodules to the point of ulceration may serve as a nidus for infection in PN patients. In addition, given that PN is reported to have a positive predictive value for a CD4 count of \<200 among HIV patients \[[@B14-medicines-06-00088]\], PN patients are also likely to be at greater risk of infection because of more frequent rates of immunosuppression. Increased frequency of end stage renal disease and congestive heart failure as reasons for admission are also consistent with prior studies showing an association between cardiovascular and renal comorbidities in patients with PN \[[@B5-medicines-06-00088],[@B15-medicines-06-00088],[@B16-medicines-06-00088]\].

Strengths of this study include the use of a nationally representative dataset with over 7 million records. Given the recent transition from ICD-9-CM to ICD-10-CM, this is the first study that provides epidemiologic data on PN in the United States. Weaknesses include the small PN sample size given the under-recognition of PN by non-dermatologic specialties. Effects of disease severity and treatment on hospitalization could also not be determined.

In conclusion, our study characterizes the inpatient burden of PN in the United States and demonstrates increased cost and length of hospital stay in the care of these patients. Our study also confirms racial differences in the burden of PN, with PN patients most likely to be black. PN patients were also found to be more likely to be admitted for infections and comorbid cardiovascular and renal conditions. Additional studies are needed to further characterize the ambulatory disease burden of PN.
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![Comparison of racial distribution. The racial distribution of patients with no prurigo nodularis (**left**) compared to patients with prurigo nodularis (**right**). The population of prurigo nodularis patients is disproportionately black compared to patients with no prurigo nodularis.](medicines-06-00088-g001){#medicines-06-00088-f001}
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medicines-06-00088-t001_Table 1

###### 

Demographics of hospitalized patients with a diagnosis of prurigo nodularis compared to the general inpatient population without a diagnosis of prurigo nodularis.

  Variable                    General Inpatient Population without a Diagnosis of Prurigo Nodularis   Patients with Prurigo Nodularis   Adjusted OR   *p*-Value                     
  --------------------------- ----------------------------------------------------------------------- --------------------------------- ------------- ---------------------- ------ ---------
  **AGE, y**                                                                                                                                                                        
  0--17                       5,479,694                                                               15.3 \[14.9--15.9\]               5             0.38 \[0.05--2.64\]    0.04   0.002
  18--39                      7,423,759                                                               20.8 \[20.5--21.0\]               210           15.8 \[11.8--20.9\]    1.00   \-\--
  40--59                      7,403,610                                                               20.7 \[20.5--21.0\]               620           46.8 \[40.2--53.5\]    2.95   \<0.001
  60--79                      10,515,272                                                              29.4 \[29.0--29.7\]               390           29.4 \[24.0--35.5\]    1.34   0.263
  \>80                        4,886,856                                                               13.7 \[13.5--13.9\]               100           7.55 \[4.83--11.60\]   0.75   0.386
  **RACE**                                                                                                                                                                          
  White                       22,141,260                                                              65.4 \[64.4--66.3\]               464           37.2 \[30.8--44.1\]    1.00   \-\--
  Black                       5,145,981                                                               15.2 \[14.6--15.8\]               550           44.0 \[37.1--51.1\]    4.43   \<0.001
  Hispanic                    4,150,991                                                               12.3 \[11.6--12.9\]               130           10.4 \[6.9--15.4\]     1.77   0.02
  Asian                       1,037,020                                                               3.06 \[2.83--3.32\]               50            4.00 \[2.22--7.09\]    2.66   0.003
  Native American             219,690                                                                 0.65 \[0.56--0.75\]               15            1.20 \[0.39--3.67\]    3.44   0.036
  Other                       1,156,259                                                               3.42 \[3.12--3.74\]               40            3.20 \[1.63--6.20\]    1.29   0.586
  **GENDER**                                                                                                                                                                        
  Female                      15,439,345                                                              43.3 \[43.1--43.5\]               635           47.9 \[41.7--54.2\]    1.00   \-\--
  Male                        20,236,076                                                              56.7 \[56.5--56.9\]               690           52.1 \[45.8--58.3\]    1.00   0.75
  **SEASON**                                                                                                                                                                        
  Winter                      8,914,808                                                               25.0 \[25.0--25.0\]               400           30.2 \[24.9--36.1\]    1.00   \-\--
  Spring                      9,015,068                                                               25.3 \[25.2--25.3\]               315           23.8 \[19.3--29.0\]    0.81   0.213
  Summer                      8,914,118                                                               25.0 \[25.0--25.0\]               305           23.0 \[18.2--28.7\]    0.73   0.106
  Fall                        8,796,723                                                               24.7 \[24.6--24.7\]               270           20.4 \[15.9--25.8\]    0.72   0.063
  **INCOME QUARTILE**                                                                                                                                                               
  First                       10,774,519                                                              30.7 \[29.8--31.6\]               465           36.9 \[30.4--43.9\]    1.00   \-\--
  Second                      8,915,683                                                               25.4 \[24.8--26.0\]               270           21.4 \[16.5--27.3\]    0.98   0.929
  Third                       8,387,702                                                               23.9 \[23.4--24.5\]               290           23.0 \[17.9--29.1\]    1.18   0.398
  Fourth                      6,999,502                                                               20.0 \[19.0--20.9\]               235           18.7 \[13.2--24.0\]    1.38   0.112
  **INSURANCE**                                                                                                                                                                     
  Medicare                    14,127,590                                                              39.6 \[39.1--40.1\]               645           49.0 \[42.8--55.4\]    2.81   \<0.001
  Medicaid                    8,241,094                                                               23.1 \[22.6--23.7\]               370           28.1 \[22.7--34.3\]    2.24   \<0.001
  Private                     10,734,828                                                              30.1 \[29.6--30.6\]               205           15.6 \[11.6--20.7\]    1.00   \-\--
  Self-pay                    1,377,983                                                               3.87 \[3.71--4.03\]               65            4.94 \[2.84--8.48\]    1.61   0.238
  No charge                   111,960                                                                 0.31 \[0.27--0.37\]               0                                           \-\--
  Other                       1,058,214                                                               2.97 \[2.77--3.19\]               30            2.28 \[1.03--4.96\]    1.28   0.612
  **INSURED**                                                                                                                                                                       
  Yes                         33,078,581                                                              92.7 \[92.5--92.9\]               1,220         92.1 \[88.0--94.9\]    1.00   \-\--
  No                          1,377,983                                                               3.86 \[3.70--4.03\]               65            4.91 \[2.81--8.42\]    1.00   \-\--
  Other or no charge          1,170,174                                                               3.28 \[3.07--3.50\]               30            2.26 \[1.03--4.92\]    1.00   \-\--
  **REGION**                                                                                                                                                                        
  Northeast                   6,599,084                                                               18.5 \[17.9--19.2\]               270           20.4 \[15.3--26.6\]    1.00   \-\--
  Midwest                     7,933,647                                                               22.2 \[21.6--22.9\]               355           26.8 \[20.2--34.6\]    1.38   0.14
  South                       14,041,126                                                              39.3 \[38.5--40.1\]               445           33.6 \[26.6--41.3\]    0.91   0.649
  West                        7,122,759                                                               20.0 \[19.4--20.6\]               255           19.2 \[14.0--25.9\]    1.25   0.328
  **TEACHING STATUS**                                                                                                                                                               
  Nonteaching                 23,291,422                                                              65.4 \[64.7--66.1\]               1,130         85.3 \[79.9--89.4\]    1.00   \-\--
  Teaching                    12,320,949                                                              34.6 \[33.9--35.3\]               195           14.7 \[10.6--20.1\]    2.60   \<0.001
  **HOSPITAL BED CAPACITY**                                                                                                                                                         
  Small                       6,674,756                                                               18.7 \[18.1--19.3\]               170           12.8 \[9.1--17.7\]     1.00   \-\--
  Medium                      10,351,226                                                              29.0 \[28.4--29.7\]               240           18.1 \[13.3--24.2\]    1.13   0.629
  Large                       18,632,207                                                              52.2 \[51.5--53.0\]               915           69.1 \[62.1--75.2\]    2.15   \<0.001

medicines-06-00088-t002_Table 2

###### 

Multivariate linear regression for the cost of care and length of stay among prurigo nodularis patients.

  Demographic                 Cost of Care   Length of Stay                                                 
  --------------------------- -------------- ------------------------- --------- ------- ------------------ -------
  **AGE, y**                                                                                                
  0--17                       Reference                                                                     
  18--39                      8980.12        \[2271.54--15688.7\]      0.009     3.46    \[0.93--5.99\]     0.007
  40--59                      10306.25       \[3295.591--17316.91\]    0.004     2.72    \[0.20--5.24\]     0.034
  60--79                      17129.11       \[8512.382--25745.83\]    \<0.001   3.74    \[0.99--6.50\]     0.008
  \>80                        7701.64        \[−1590.12--16993.42\]    0.104     1.06    \[−2.43--4.57\]    0.55
  **SEASON**                                                                                                
  Winter                      Reference                                                                     
  Spring                      2428.98        \[−3651.91--8509.88\]     0.433     0.34    \[−2.05--2.74\]    0.776
  Summer                      −2276.29       \[−6883.1--2330.51\]      0.333     −2.08   \[−4.08--−0.08\]   0.041
  Fall                        −1365.68       \[−6400.697--3669.33\]    0.595     −2.06   \[−4.28--0.15\]    0.069
  **GENDER**                                                                                                
  Female                      Reference                                                                     
  Male                        −2927.89       \[-7155.95--1300.16\]     0.175     −0.23   \[−1.84--1.38\]    0.781
  **RACE**                                                                                                  
  White                       Reference                                                                     
  Black                       −696.01        \[−5725.16--4333.13\]     0.786     0.18    \[−2.06--2.42\]    0.875
  Hispanic                    2806.11        \[−4865.536--10477.76\]   0.473     −0.28   \[−2.97--2.42\]    0.841
  Asian                       5474.29        \[−1684.91--12633.5\]     0.134     −0.38   \[−3.27--2.50\]    0.794
  Native American             5100.59        \[−9957.69--20158.88\]    0.507     4.44    \[−3.10--11.99\]   0.248
  Other                       −6695.23       \[−14271.62--881.14\]     0.083     −2.55   \[−5.51--0.41\]    0.092
  **INCOME QUARTILE**                                                                                       
  First                       Reference                                                                     
  Second                      1357.71        \[−4561.79--7277.22\]     0.653     1.47    \[−1.26--4.20\]    0.29
  Third                       −326.29        \[−4849.39--4196.79\]     0.888     0.25    \[−1.59--2.09\]    0.793
  Fourth                      2211.26        \[−5600.19--10022.73\]    0.579     −0.41   \[−2.73--1.90\]    0.725
  **INSURANCE**                                                                                             
  Medicare                    3799.07        \[−2029.32--9627.46\]     0.201     2.14    \[−0.31--4.59\]    0.87
  Medicaid                    4274.12        \[−666.47--9214.72\]      0.09      2.14    \[−0.07--4.35\]    0.058
  Private                     Reference                                                                     
  Self-pay                    −200.49        \[−6367.36--5966.37\]     0.949     0.23    \[−2.88--3.32\]    0.886
  No charge                                                                                                 
  Other                       355.35         \[−8232.30--8943.01\]     0.935     3.37    \[−0.96--7.70\]    0.127
  **REGION**                                                                                                
  Northeast                   Reference                                                                     
  Midwest                     1947.42        \[−5246.55--9141.39\]     0.596     −0.84   \[−3.76--2.08\]    0.573
  South                       951.9          \[−4984.18--6888.00\]     0.753     0.12    \[−2.44--2.68\]    0.929
  West                        2914.19        \[−4681.94--10510.34\]    0.452     −0.48   \[−3.35--2.40\]    0.745
  **TEACHING STATUS**                                                                                       
  Nonteaching                 Reference                                                                     
  Teaching                    1639.64        \[−2697.30--5976.59\]     0.459     −0.22   \[−2.15-1.70\]     0.819
  **HOSPITAL BED CAPACITY**                                                                                 
  Small                       Reference                                                                     
  Medium                      5096.48        \[−1453.24--11646.2\]     0.127     0.51    \[−2.35--3.37\]    0.727
  Large                       7446.41        \[1527.81--13365.01\]     0.014     0.6     \[−1.57--2.77\]    0.587
